Posted November 01, 2021
Japan-based Sumitomo Dainippon Pharma has teamed up with BehaVR to jointly develop and market prescription digital therapeutics and general wellness products for various mental disorders.
The mental disorders include social anxiety disorder (SAD), generalized anxiety disorder (GAD), and major depressive disorder (MDD).
Based in Tennessee, US, BehaVR is engaged in developing treatments for anxiety-related disorders, using the neurological power of VR.
Under the terms of the collaboration, the Japanese drugmaker will fund the development of novel VR therapies and commercialise them worldwide, upon receiving regulatory approvals.
BehaVR will receive an upfront payment of $5m, along with up to $18m in development milestone and R&D support payments.